Form 4: LENZ Therapeutics Director Frederic Guerard Granted 13,500 Stock Options

LENZ Therapeutics, Inc. Director Frederic Guerard was granted 13,500 stock options with an exercise price of $30, vesting fully on June 11, 2026.

Summary

• Frederic Guerard, a Director of LENZ Therapeutics, Inc. (LENZ), was granted 13,500 stock options.
• The options have an exercise price of $30 per share.
• The options are scheduled to vest 100% on June 11, 2026, contingent upon Mr. Guerard continuing to serve as an Outside Director.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Frederic Guerard beneficially owns 13,500 derivative securities (stock options) directly.
• A Power of Attorney was executed on June 11, 2025, authorizing specific individuals to file SEC reports on behalf of Frederic Guerard.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns the director's interests with those of the shareholders, fostering long-term commitment and performance.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance of LENZ Therapeutics, Inc., potentially incentivizing value creation for shareholders.
• This is a standard form of equity compensation for board members, reinforcing commitment and retention.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholders' equity, although this is a common aspect of equity compensation plans.

Risks

• The vesting of the 13,500 stock options is subject to Frederic Guerard continuing to be an Outside Director through the vesting date of June 11, 2026.

Future Outlook

The granted stock options are set to fully vest on June 11, 2026, provided Frederic Guerard continues his role as an Outside Director.

Management Comments

• The Power of Attorney acknowledges that it authorizes, but does not require, the Attorney-in-Fact to act on information provided without independent verification.
• The Power of Attorney states that neither the Company nor the Attorney-in-Fact assumes liability for the undersigned's responsibility to comply with Section 13 or Section 16 of the Exchange Act or Rule 144, or for any failure to comply or disgorgement of profits.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically an equity grant to a director, which is a common practice across publicly traded companies in various industries to incentivize and retain key personnel.

Corporate Governance

Related Party Transactions

• Grant of 13,500 stock options to Frederic Guerard, a Director of LENZ Therapeutics, Inc., which constitutes a transaction with a related party.

Stakeholder Impact

• **Shareholders**: Potential for minor future dilution if options are exercised, but also increased alignment of the director's interests with shareholder value creation.
• **Frederic Guerard (Director)**: Receives equity compensation, providing a direct financial incentive tied to the company's stock performance and continued service.

Next Steps

• Vesting of 100% of the granted stock options on June 11, 2026, subject to Frederic Guerard continuing as an Outside Director.

Key Dates

Keywords

LENZ Therapeutics, LENZ, Frederic Guerard, Stock Option, Director Compensation, Insider Transaction, Equity Grant, SEC Form 4, Beneficial Ownership